| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 15:30 | SAF Group launches insurance-backed vehicle to expand private credit - Bloomberg | ||
| 15:30 | First Bancorp announces $0.23 per share quarterly dividend | ||
| 15:30 | Revolut expands wealth offering with new private markets team - Bloomberg | ||
| 15:30 | Geode Capital discloses 2.24% stake in Avadel Pharmaceuticals | ||
| 15:30 | The Chefs' Warehouse stock rating reiterated at Buy by Benchmark | ||
| 15:30 | Truist Securities reiterates Buy rating on Eli Lilly stock at $1,182 | ||
| 15:30 | Truist Securities lowers Costco stock price target to $926 on slower member growth | ||
| 15:30 | PACS Group stock price target raised to $40 from $32 at Truist Securities | ||
| 15:18 | Xtrackers ETC plc issues new tranche of silver securities | ||
| 15:18 | Zhibao Technology begins operations of new joint venture in China | ||
| 15:18 | PPG announces leadership changes as Latin America VP plans retirement | ||
| 15:18 | Ananda Pharma shareholders approve delisting from AQSE Growth Market | ||
| 15:18 | VivoPower forms joint venture to acquire $300 million in Ripple Labs shares | ||
| 15:18 | Actelis Networks receives first order for hospitality connectivity solution | ||
| 15:18 | Broadcom stock price target raised to $485 from $385 at Benchmark on AI growth | ||
| 15:18 | Applied Therapeutics stock rating downgraded to Neutral by Baird | ||
| 15:18 | BMO Capital reiterates Outperform on Eli Lilly stock after strong TRIUMPH-4 data | ||
| 15:18 | Empire Company stock price target lowered to C$51 by BMO Capital | ||
| 15:06 | WUXI, China - Lobo Technologies onboards solar team to expand into PV market | ||
| 15:06 | EU panel recommends expanded indication for Merck's PAH drug | ||
| 15:06 | Charles Schwab reports $40.4 billion in core net new assets for November | ||
| 15:06 | Actinium's breast cancer therapy shows promise in preclinical studies | ||
| 15:06 | GSK's Nucala receives positive CHMP opinion for COPD treatment | ||
| 15:06 | EMA committee recommends approval of Cytokinetics' oHCM drug | ||
| 15:06 | D2L stock price target lowered to C$17 by BMO Capital on K-12 churn |